Supernus Pharmaceuticals Stock
Your prediction
Supernus Pharmaceuticals Stock
Pros and Cons of Supernus Pharmaceuticals in the next few years
Pros
Cons
Performance of Supernus Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals | -2.130% | -6.122% | -8.609% | -17.365% | 5.344% | 6.154% | -16.855% |
| Gritstone Oncology Inc | 0.410% | -20.034% | -67.793% | -73.006% | -62.298% | -90.291% | - |
| Pacira Pharmaceuticals | 3.310% | -2.344% | -5.303% | -35.567% | -16.107% | -52.381% | -20.936% |
| Cocrystal Pharma Inc. | - | -7.143% | -3.704% | -39.252% | -16.129% | -88.715% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Supernus Pharma, a pharmaceutical company specializing in central nervous system drugs, appears to exhibit a dynamic financial performance. A deep dive into its financial statements shows that the company has demonstrated growth in revenue and net income over the past years. While some financial aspects of Supernus Pharma may be viewed positively, a comprehensive understanding of its financials also necessitates examining the risks.
Revenue growth: The company's total revenue has been on an upward trajectory, growing from $520.4 million in 2020 to $579.78 million in 2021 and further to $667.24 million in 2022. This consistent growth suggests that the company enjoys a healthy demand for its products, a positive indication of the company's business strategy and market presence.
Increase in gross profit: Supernus Pharma's gross profit has seen a steady increase during the last three years, rising from $467.94 million in 2020 to $504.71 million in 2021 and $580.02 million in 2022. This upward trend signals that the company is successful in controlling the cost of goods sold, potentially contributing to higher profit margins.
